The National Institutes of Health (NIH) has awarded Texas Biomedical Research Institute staff scientist Ian Cheeseman, PhD, more than $450,000 in first-year funding and is expected to receive up to $1.8 million over four years to continue research into a new method for sequencing the genomes of individual malaria parasites, which he and colleagues at Texas Biomed developed and announced earlier this year in the journal Genome Research.
This research will allow scientists to improve their ability to characterize malaria parasites infecting patients. Each malaria infection can contain multiple genetically distinct strains of malaria parasites, each of which may affect disease progression differently. Until now, scientists lacked the tools to characterize the genomes of these individual malaria parasites.
“We think about these infections as containing the sort of diversity you would see in a human village,” Cheeseman says. “We could previously only look at the village as a whole, but new technology developed here at Texas Biomed now allows us to identify everyone in the village directly.”
Single cell genomics was pioneered in cancer research to identify how tumors evolve during the progression of a disease, but it has been difficult to adapt them to other organisms, according to Cheeseman.
“One of the major surprises we found when we started looking at individual parasites instead of whole infections was the level of variation in drug resistance genes,” says Shalini Nair, a colleague of Cheeseman’s in the Department of Genetics at Texas Biomed. “The patterns we saw suggested that different parasites within a single malaria infection would react very differently to drug treatment.”
According to the World Health Organization, malaria remains the world’s deadliest parasitic disease, killing 627,000 people in 2012, many of whom were children younger than five. “We’re now able to look at malaria infections with incredible detail,” Cheeseman adds. “This will help us understand how to best design drugs and vaccines to tackle this major global killer.”
At 31, Cheeseman is one of the youngest recipients of such an award in the country. In 2010 only 17 of 26,183 NIH R01 funded scientists were aged 31 and under, according to an NIH report on the age of RO1 principal investigators from 1980 to 2010.
“To be able to embark on such a well-supported research project so early in my career is a phenomenal boost,” says Cheeseman, whose early research was supported by Texas Biomedical Forum funding.
This research is being supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI110941.
Source: Texas Biomedical Research Institute